At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 94 enrolled
Drug / intervention
Baricitinib 4 MG Oral Tablet +1 moredrug
Likely dose
Baricitinib 4 MG Oral Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Baricitinib in Different Doses for the Treatment of Moderate to Severe Rheumatoid Arthritis
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh·interventional·Posted Dec 21, 2022·Updated Nov 18, 2023
In Brief
A Phase 4 clinical trial evaluating Baricitinib 4 MG Oral Tablet and Baricitinib 2 MG for Rheumatoid Arthritis. Completed, enrolled 94 participants across 1 site.
Detailed Summary
This is a randomized controlled study. Baricitinib 4mg in one arm and Baricitinib 2mg in another arm will be used. Methotrexate 10mg per week in both arms will be used.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBangladesh
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
Enrollment StartOct 2022
First PostedDec 2022
Primary CompletionSep 2023
TodayJul 2026
First PostedDec 21, 2022
Enrollment StartOct 1, 2022
Primary CompletionSep 30, 2023
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 3.5 years ago
Interventions
Baricitinib 4 MG Oral Tabletdrug
baricitinib 4 mg once daily
Baricitinib 2 MGdrug
baricitinib 4mg once daily in group A